123855-86-7

Upstream product

• 121-17-5 2-chloro-3-nitro-5-trifluoromethylbenzene 
• 95-92-1 oxalic acid diethyl ester 
• 87815-78-9 N-cyclohexyl-2-nitro-4-(trifluoromethyl)aniline 
• 4755-77-5 Ethyl oxalyl chloride 
• 108-91-8 cyclohexylamine 

Downstream Products

• 154017-58-0 1-cyclohexyl-6-trifluoromethyl-7-amino-2,3(1H,4H)-quinoxalinedione 
• 154017-57-9 1-cyclohexyl-6-trifluoromethyl-7-nitro-2,3(1H,4H)-quinoxalinedione 

Relevant academic research and scientific papers

2,3(1H,4H)quinoxalinedione

2,3(1H,4H)-quinoxalinediones of the formula I STR1 where R1 is hydrogen, an aliphatic radical which has up to 12 carbons and can be substituted by one of the following: phenyl, cyclopentyl, cyclohexyl or --CO--R3, --CO--O--R3 or --CO--NH--R3, where R3 is hydrogen, C1 -C4 -alkyl, phenyl, benzyl or 1-phenylethyl, a cycloaliphatic radical with up to 12 carbons or phenyl, where the cyclic groups in R1 can have up to three of the following substituents: C1 -C4 -alkyl, C1 -C4 -haloalkyl, C1 -C4 -alkoxy, C1 -C4 -haloalkoxy, halogen, nitro, cyano, --CO--O--R3 and --CO--NH--R3 ; R2 is 1-pyrrolyl which can have up to two of the following substituents: C1 -C4 -alkyl, phenyl, phenylsulfonyl, nitro, cyano and --CO--O--R3, --CO--NH--R3, --CH2 --O--R3, --O--R3 and --CH=NO--R3 R radicals are identical or different and are the following: C1 -C4 -alkyl, C1 -C4 -alkoxy, trifluoromethyl, trichloromethyl, trifluoromethoxy, trichloromethoxy, fluorine, chlorine, bromine, iodine, nitro, cyano and --CO--O--R3 and --CO--NH--R3 as well as a fused-on benzene ring; n is 0-3, and 2,3(1H,4H)-quinoxalinediones I' STR2 where R1 has the stated meanings, are suitable as drugs in the treatment of neurodegenerative disorders and neurotoxic disturbances of the central nervous system.

Pyrrolylquinoxalinediones: A new class of AMPA receptor antagonists

Pyrrolylquinoxalinediones were synthesized and their affinities for the AMPA receptor were determined. Most compounds showed moderate to good affinities. The acetic acid derivative 8b exhibited a K(i) value of 70 nM and was equipotent to NBQX 1. Structure activity relationships are discussed. Selected compounds were tested for their potency to inhibit AMPA induced lethal convulsions in mice. In this in vivo model the compounds showed improved potency compared with NBQX.

Cycloalkyl or benzyl-6-substituted-quinoxalinediones

Heterocyclic dihydroxyquinoxaline compounds having the formula STR1 wherein R 1 is C 1-12 -alkyl, which may optionally be substituted by hydroxy, formyl, carboxy, carboxylic esters, amides or amines, C 3-8 -cycloalkyl, aryl, aralkyl; and wherein R 6 is, hydrogen, halogen, CN, CF 3, NO 2, or OR'', wherein R'' is C 1-4 -alkyl and R 5, R 7 and R 8 is hydrogen, provided R 6 is not CF 3, OCH 3, NO 2, C 1 or Br when R 1 is CH 3 ; orR 6 and R 7 independently are NO 2, halogen, CN, CF 3, or OR'', wherein R'' is C 1-4 -alkyl, and R 5 and R 8 are each hydrogen; orR 5 and R 6 together form a further fused aromatic ring, which may be substituted with halogen, NO 2, CN, CF 3 or OR'', wherein R'' is C 1-4 -alkyl, and R 7 and R 8 independently are hydrogen, halogen, CN, CF 3, NO 2 or OR'', wherein R'' is C 1-4 -alkyl; orR 7 and R 8 together form a further fused aromatic ring, which may be substituted with halogen, NO 2, CN, CF 3 or OR'', wherein R'' is C 1-4 -alkyl, and R 5 and R 6 independently are hydrogen, halogen, CN, CF 3, NO 2 or OR'', wherein R'' is C 1-4 -alkyl.The invention also relates to a method of preparing the compounds, pharmaceutical compositions thereof, and their use.The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters, particularly the quisqualate receptors, and especially as neuroleptics.